Literature DB >> 26504020

Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.

Andrew M Baschnagel1, Sandra Galoforo2, Bryan J Thibodeau3, Samreen Ahmed3, Sonali Nirmal3, Jan Akervall4, George D Wilson5.   

Abstract

AIM: Mesenchymal-epithelial transition factor (MET), a receptor tyrosine kinase, is expressed in head and neck squamous cell carcinomas (HNSCC) and is involved in tumor progression and associated with poor prognosis. MET can be inhibited by crizotinib, a potent ATP-competitive kinase inhibitor. We examined the effects of combining crizotinib and radiation in a pre-clinical HNSCC model.
MATERIALS AND METHODS: Nine HNSCC cell lines were screened for MET expression, copy-number amplification and mutational status. The in vitro effects of crizotinib and radiation were assessed with clonogenic survival assays. MET signaling proteins were assessed with western blot and receptor tyrosine kinase array. Tumor growth-delay experiments with UT-SCC-14 and UT-SCC-15 oral tongue xenografts were used to assess in vivo tumor radiosensitivity.
RESULTS: All nine HNSCC cell lines showed a varying degree of MET protein and RNA expression. Increased MET copy number was not present. MET was expressed after irradiation both in vitro and in vivo. Crizotinib alone inhibited phosphorylation of MET and inhibited cell growth in vitro but did not inhibit phosphorylation of downstream signaling proteins: MAPK, AKT or c-SRC. When combined with radiation in vitro, crizotinib demonstrated radiation enhancement in only one cell line. Crizotinib did not enhance the effect of radiation in either UT-SCC-14 or UT-SCC-15 tumors grown as xenografts.
CONCLUSION: MET is overexpressed in HNSCC cell lines, however, crizotinib failed to enhance the radiation response and failed to inhibit MET downstream signaling proteins in this HNSCC model. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  HGF; MET; c-MET; crizotinib; head and neck cancer; radiation

Mesh:

Substances:

Year:  2015        PMID: 26504020

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer.

Authors:  George D Wilson; Thomas G Wilson; Alaa Hanna; Mohamad Dabjan; Katie Buelow; John Torma; Brian Marples; Sandra Galoforo
Journal:  Clin Transl Radiat Oncol       Date:  2020-11-08

Review 2.  HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.

Authors:  Stefan Hartmann; Neil E Bhola; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2016-07-01       Impact factor: 12.531

Review 3.  Activated HGF-c-Met Axis in Head and Neck Cancer.

Authors:  Levi Arnold; Jonathan Enders; Sufi Mary Thomas
Journal:  Cancers (Basel)       Date:  2017-12-12       Impact factor: 6.575

Review 4.  Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials.

Authors:  Choudhary Harsha; Kishore Banik; Hui Li Ang; Sosmitha Girisa; Rajesh Vikkurthi; Dey Parama; Varsha Rana; Bano Shabnam; Elina Khatoon; Alan Prem Kumar; Ajaikumar B Kunnumakkara
Journal:  Int J Mol Sci       Date:  2020-05-06       Impact factor: 5.923

5.  Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases.

Authors:  Andrew M Baschnagel; Saakshi Kaushik; Arda Durmaz; Steve Goldstein; Irene M Ong; Lindsey Abel; Paul A Clark; Zafer Gurel; Ticiana Leal; Darya Buehler; Gopal Iyer; Jacob G Scott; Randall J Kimple
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

6.  Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast-conserving surgery: a long-term follow-up of the SweBCG91-RT randomised trial.

Authors:  Martin Sjöström; Cynthia Veenstra; Erik Holmberg; Per Karlsson; Fredrika Killander; Per Malmström; Emma Niméus; Mårten Fernö; Olle Stål
Journal:  Mol Oncol       Date:  2020-09-28       Impact factor: 7.449

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.